BioMedReports FDA Calendar: Seven New Extreme Trades
Bullish Bankers (June 22nd, 2009) Writes:
Below are companies with market caps under $250 million from the BioMedReports.com FDA Calendar, which have either pending FDA decisions or pending clinical trial results that may have a major impact on each of the underlying stock prices. A high risk/reward trading approach to consider for speculative traders is investing a small amount of money that you can afford to lose in a basket of stocks included in Extreme FDA and Clinical Trial Calendar Trades, which are highlighted in periodic articles at BioMedReports.com. Another approach is to simply buy such companies well ahead of their expected catalyst dates for a possible stock price increase as the date approaches and trading activity increases.
BioMimetic Therapeutics [BMTI: 9.07, -0.52 (-5.42%)]: On 6/17/09, BMTI announced that it has submitted both the pre-clinical pharmacology/toxicology and quality/manufacturing modules of its Premarket Approval (PMA) application for marketing of Augment Bone Graft
...3Q09;, Breast Cancer, bullish bankers, drug delivery system;, Dyloject, Executive Committee;, Fda, Financial, Fluocinolone acetonide, GATTEX, hypoactive sexual desire disorder, hypoparathyroidism, Iluvien, Javelin Pharmaceuticals Inc.;, LibiGel, LibiGel Safety Study External, LibiGel Safety Study External Executive Committee, macular degeneration, Macular Edema, Market Commentary, National Park Service;, NPSP558, original author, pain, parenteral nutrition, pSivida Corp., retinitis pigmentosa, Securities And Exchange Commission, short bowel syndrome, treatment of hypoactive sexual desire disorder, United Kingdom, United States


![[Most Recent Quotes from www.kitco.com]](http://www.kitconet.com/charts/metals/gold/t24_au_en_usoz_2.gif)
![[Most Recent Quotes from www.kitco.com]](http://www.kitconet.com/charts/metals/silver/t24_ag_en_usoz_2.gif)
